{"id":42459,"date":"2025-09-29T17:09:38","date_gmt":"2025-09-29T09:09:38","guid":{"rendered":"https:\/\/flcube.com\/?p=42459"},"modified":"2025-09-29T17:09:39","modified_gmt":"2025-09-29T09:09:39","slug":"eisai-biogen-secure-leqembi-china-maintenance-approval","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=42459","title":{"rendered":"Eisai\u202f&amp;\u202fBiogen Secure Leqembi China Maintenance Approval"},"content":{"rendered":"\n<p>Japanese drugmaker <strong>Eisai Co., Ltd. (<a href=\"https:\/\/www.google.com\/finance\/quote\/4523:TYO\">TYO: 4523<\/a>)<\/strong> and U.S. biopharma <strong>Biogen Inc. (<a href=\"https:\/\/www.google.com\/finance\/quote\/BIIB:NASDAQ\">NASDAQ: BIIB<\/a>)<\/strong> announced that the <strong>National Medical Products Administration (NMPA)<\/strong> has cleared the <strong>once\u2011every\u2011four\u2011weeks Leqembi (lecanemab) IV maintenance regimen<\/strong> for patients with mild cognitive impairment (MCI) and mild Alzheimer\u2019s disease (AD) in China.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-what-the-approval-means\">What the Approval Means<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Maintenance Dosing Flexibility<\/strong> \u2013 After the 18\u2011month, every\u2011two\u2011weeks induction phase, patients may switch to a <strong>10\u202fmg\/kg every\u2011four\u2011weeks<\/strong> maintenance schedule, or continue the bi\u2011weekly dose.<\/li>\n\n\n\n<li><strong>Targeted Mechanism<\/strong> \u2013 Leqembi binds soluble and insoluble amyloid\u2011\u03b2 (A\u03b2) aggregates, reducing both proto\u2011fibrils and plaques that drive cognitive decline.<\/li>\n\n\n\n<li><strong>Regulatory Milestone<\/strong> \u2013 The NMPA decision follows Leqembi\u2019s 2024 approval for MCI and mild AD, marking the first Chinese authorization of an anti\u2011A\u03b2 therapy with a simplified maintenance schedule.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-strategic-impact\">Strategic Impact<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>For Manufacturers<\/strong> \u2013 The simplified dosing is expected to lower logistics costs, improve patient adherence, and expand the market for Eisai and Biogen in China\u2019s growing neurodegenerative\u2011disease sector.<\/li>\n\n\n\n<li><strong>For Patients<\/strong> \u2013 Fewer clinic visits may translate to a better quality of life and reduced treatment burden for thousands of patients with early\u2011stage Alzheimer\u2019s.<\/li>\n\n\n\n<li><strong>For the Market<\/strong> \u2013 The approval positions Leqembi as a leading therapeutic option in China, potentially reshaping the competitive landscape dominated by symptomatic treatments.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-investor-takeaway\">Investor Takeaway<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Revenue Upside<\/strong> \u2013 Easier maintenance dosing could accelerate uptake, boosting sales for both partners in a market projected to reach USD\u202f3\u202fbillion by 2030.<\/li>\n\n\n\n<li><strong>Strategic Partnerships<\/strong> \u2013 The collaboration underscores a trend toward joint development and licensing deals to navigate China\u2019s stringent regulatory environment.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Japanese drugmaker Eisai Co., Ltd. (TYO: 4523) and U.S. biopharma Biogen Inc. (NASDAQ: BIIB) announced&#8230;<\/p>\n","protected":false},"author":1,"featured_media":42462,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[351,350,993,15,1151],"class_list":["post-42459","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-biogen","tag-eisai","tag-nasdaq-biib","tag-product-approvals","tag-tyo-4523"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Eisai\u202f&amp;\u202fBiogen Secure Leqembi China Maintenance Approval - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Japanese drugmaker Eisai Co., Ltd. (TYO: 4523) and U.S. biopharma Biogen Inc. (NASDAQ: BIIB) announced that the National Medical Products Administration (NMPA) has cleared the once\u2011every\u2011four\u2011weeks Leqembi (lecanemab) IV maintenance regimen for patients with mild cognitive impairment (MCI) and mild Alzheimer\u2019s disease (AD) in China.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=42459\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eisai\u202f&amp;\u202fBiogen Secure Leqembi China Maintenance Approval\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=42459\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-29T09:09:38+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-29T09:09:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2902.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42459#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42459\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Eisai\u202f&amp;\u202fBiogen Secure Leqembi China Maintenance Approval\",\"datePublished\":\"2025-09-29T09:09:38+00:00\",\"dateModified\":\"2025-09-29T09:09:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42459\"},\"wordCount\":267,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42459#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/2902.webp\",\"keywords\":[\"Biogen\",\"Eisai\",\"NASDAQ: BIIB\",\"Product approvals\",\"TYO: 4523\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=42459#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42459\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=42459\",\"name\":\"Eisai\u202f&amp;\u202fBiogen Secure Leqembi China Maintenance Approval - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42459#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42459#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/2902.webp\",\"datePublished\":\"2025-09-29T09:09:38+00:00\",\"dateModified\":\"2025-09-29T09:09:39+00:00\",\"description\":\"Japanese drugmaker Eisai Co., Ltd. (TYO: 4523) and U.S. biopharma Biogen Inc. (NASDAQ: BIIB) announced that the National Medical Products Administration (NMPA) has cleared the once\u2011every\u2011four\u2011weeks Leqembi (lecanemab) IV maintenance regimen for patients with mild cognitive impairment (MCI) and mild Alzheimer\u2019s disease (AD) in China.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42459#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=42459\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42459#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/2902.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/2902.webp\",\"width\":1080,\"height\":608,\"caption\":\"Eisai\u202f&\u202fBiogen Secure Leqembi China Maintenance Approval\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42459#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eisai\u202f&amp;\u202fBiogen Secure Leqembi China Maintenance Approval\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Eisai\u202f&amp;\u202fBiogen Secure Leqembi China Maintenance Approval - Insight, China&#039;s Pharmaceutical Industry","description":"Japanese drugmaker Eisai Co., Ltd. (TYO: 4523) and U.S. biopharma Biogen Inc. (NASDAQ: BIIB) announced that the National Medical Products Administration (NMPA) has cleared the once\u2011every\u2011four\u2011weeks Leqembi (lecanemab) IV maintenance regimen for patients with mild cognitive impairment (MCI) and mild Alzheimer\u2019s disease (AD) in China.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=42459","og_locale":"en_US","og_type":"article","og_title":"Eisai\u202f&amp;\u202fBiogen Secure Leqembi China Maintenance Approval","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=42459","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-09-29T09:09:38+00:00","article_modified_time":"2025-09-29T09:09:39+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2902.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=42459#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=42459"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Eisai\u202f&amp;\u202fBiogen Secure Leqembi China Maintenance Approval","datePublished":"2025-09-29T09:09:38+00:00","dateModified":"2025-09-29T09:09:39+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=42459"},"wordCount":267,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=42459#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2902.webp","keywords":["Biogen","Eisai","NASDAQ: BIIB","Product approvals","TYO: 4523"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=42459#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=42459","url":"https:\/\/flcube.com\/?p=42459","name":"Eisai\u202f&amp;\u202fBiogen Secure Leqembi China Maintenance Approval - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=42459#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=42459#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2902.webp","datePublished":"2025-09-29T09:09:38+00:00","dateModified":"2025-09-29T09:09:39+00:00","description":"Japanese drugmaker Eisai Co., Ltd. (TYO: 4523) and U.S. biopharma Biogen Inc. (NASDAQ: BIIB) announced that the National Medical Products Administration (NMPA) has cleared the once\u2011every\u2011four\u2011weeks Leqembi (lecanemab) IV maintenance regimen for patients with mild cognitive impairment (MCI) and mild Alzheimer\u2019s disease (AD) in China.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=42459#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=42459"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=42459#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2902.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2902.webp","width":1080,"height":608,"caption":"Eisai\u202f&\u202fBiogen Secure Leqembi China Maintenance Approval"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=42459#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Eisai\u202f&amp;\u202fBiogen Secure Leqembi China Maintenance Approval"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2902.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/42459","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=42459"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/42459\/revisions"}],"predecessor-version":[{"id":42465,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/42459\/revisions\/42465"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/42462"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=42459"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=42459"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=42459"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}